| Systematic review with meta‐analysis: malignancies with anti‐tumour necrosis factor‐α therapy in inflammatory bowel disease CJM Williams, L Peyrin‐Biroulet, AC Ford Alimentary pharmacology & therapeutics 39 (5), 447-458, 2014 | 186 | 2014 |
| Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease DJ Gracie, CJM Williams, R Sood, S Mumtaz, HM Bholah, JP Hamlin, ... American Journal of Gastroenterology 111 (4), 541-551, 2016 | 153 | 2016 |
| Negative effects on psychological health and quality of life of genuine irritable bowel syndrome–type symptoms in patients with inflammatory bowel disease DJ Gracie, CJM Williams, R Sood, S Mumtaz, MH Bholah, PJ Hamlin, ... Clinical Gastroenterology and Hepatology 15 (3), 376-384. e5, 2017 | 140 | 2017 |
| The relationship between different information sources and disease‐related patient knowledge and anxiety in patients with inflammatory bowel disease CP Selinger, I Carbery, V Warren, AF Rehman, CJ Williams, S Mumtaz, ... Alimentary pharmacology & therapeutics 45 (1), 63-74, 2017 | 56 | 2017 |
| Clinical efficacy of an optimized stannous fluoride dentifrice, Part 3: A 6-month plaque/gingivitis clinical study, southeast USA. C Williams, S McBride, TE Bolden, K Mostler, DM Petrone, ME Petrone, ... Compendium of Continuing Education in Dentistry (Jamesburg, NJ: 1995) 18, 16-20, 1997 | 36 | 1997 |
| Efficacy of a dentifrice containing zinc citrate for the control of plaque and gingivitis: a 6-month clinical study in adults. C Williams, S McBride, K Mostler, DM Petrone, AJ Simone, R Crawford, ... Compendium of Continuing Education in Dentistry (Jamesburg, NJ: 1995) 19 (2 …, 1998 | 33 | 1998 |
| Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin Y Derwa, CJM Williams, R Sood, S Mumtaz, MH Bholah, CP Selinger, ... Therapeutic Advances in Gastroenterology 11, 1756283X17744739, 2018 | 22 | 2018 |
| Artificial Intelligence–Assisted Amphiregulin and Epiregulin IHC Predicts Panitumumab Benefit in RAS Wild-Type Metastatic Colorectal Cancer CJM Williams, JF Seligmann, F Elliott, M Shires, SD Richman, S Brown, ... Clinical Cancer Research 27 (12), 3422-3431, 2021 | 18* | 2021 |
| Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of … JF Seligmann, F Elliott, S Richman, G Hemmings, S Brown, B Jacobs, ... Annals of Oncology 31 (8), 1021-1029, 2020 | 15 | 2020 |
| 552O FOxTROT: Results of embedded phase II evaluating the addition of panitumumab (pan) to neo-adjuvant FOLFOX for patients (pts) with KRAS-wt colon cancer (CC) with extended … J Seligmann, D Morton, M Seymour, F Elliott, K Handley, B Glimelius, ... Annals of Oncology 34, S412, 2023 | 4 | 2023 |
| Higher Ground: A Panel Discussion on Questlove’s Summer of Soul C Williams, MA Weber, FM Hadley, S Brown, T Bolden The Langston Hughes Review 29 (2), 150-173, 2023 | 1 | 2023 |
